Clinical Trial

A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study was designed to compare the efficacy and safety of MHB088C for Injection with treatment of physician's choice (TPC) in participants with relapsed small cell lung cancer (SCLC).
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-04-24.
Status change: Not Yet Recruiting → Recruiting 2025-06-15
Trial Details
NCT Number NCT06954246
Lead Sponsor Qilu Pharmaceutical Co., Ltd.
Conditions Small Cell Lung Cancer Extensive Stage
Enrollment 450 participants
Start Date 2025-06-04
Primary Completion 2027-05 (estimated)
Study Completion 2028-04 (estimated)
Updated on ClinicalTrials.gov 2025-06-18